BR0309921A - Toxina relacionada a polipetìdeos, peptìdeo-mimético, anticorpo e ácido nucléico com atividade antimicrobiana e antiviral, bem como seu processo de preparação, sua composição farmacêutica e fabricação do medicamento - Google Patents

Toxina relacionada a polipetìdeos, peptìdeo-mimético, anticorpo e ácido nucléico com atividade antimicrobiana e antiviral, bem como seu processo de preparação, sua composição farmacêutica e fabricação do medicamento

Info

Publication number
BR0309921A
BR0309921A BR0309921-0A BR0309921A BR0309921A BR 0309921 A BR0309921 A BR 0309921A BR 0309921 A BR0309921 A BR 0309921A BR 0309921 A BR0309921 A BR 0309921A
Authority
BR
Brazil
Prior art keywords
polypeptides
antibody
antiviral activity
mimetic
antimicrobial
Prior art date
Application number
BR0309921-0A
Other languages
English (en)
Inventor
Paolo Neri
Luisa Bracci
Luisa Lozzi
Original Assignee
Univ Siena
Luciano Polonelli
Antonio Cassone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Siena, Luciano Polonelli, Antonio Cassone filed Critical Univ Siena
Publication of BR0309921A publication Critical patent/BR0309921A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"TOXINA RELACIONADA A POLIPEPTìDIOS, PEPTìDEO-MIMéTICO, ANTICORPO E áCIDO NUCLéICO COM ATIVIDADE ANTIMICROBIANA E ANTIVIRAL, BEM COMO SEU PROCESSO DE PREPARAçãO, SUA COMPOSIçãO FARMACêUTICA E FABRICAçãO DO MEDICAMENTO". Anticorpos anti-idiótipos os quais reconhecem o idiótipo de um anticorpo específico levedura da toxina letal que possui atividade microbicida. Fragmentos (e.g. decapeptídeos) destes anticorpos anti-idiótipos , particularmente aqueles compreendendo resíduos de CDR, também mostram atividade microbicida, como fazem os peptídeos possuindo 5 na mesma seq³ência mas compostos de aminoácidos D, ou incluindo substituições de aminoácidos. Peptídeo-miméticos desses polipeptídios microbicidas também são fornecidos. Atividade antiviral é também vista.
BR0309921-0A 2002-05-10 2003-05-09 Toxina relacionada a polipetìdeos, peptìdeo-mimético, anticorpo e ácido nucléico com atividade antimicrobiana e antiviral, bem como seu processo de preparação, sua composição farmacêutica e fabricação do medicamento BR0309921A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0210783.7A GB0210783D0 (en) 2002-05-10 2002-05-10 Anti-microbial polypeptides
PCT/IB2003/002348 WO2003095493A2 (en) 2002-05-10 2003-05-09 Toxin-related antibodies with antimicrobial and antiviral activity

Publications (1)

Publication Number Publication Date
BR0309921A true BR0309921A (pt) 2005-02-09

Family

ID=9936462

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309921-0A BR0309921A (pt) 2002-05-10 2003-05-09 Toxina relacionada a polipetìdeos, peptìdeo-mimético, anticorpo e ácido nucléico com atividade antimicrobiana e antiviral, bem como seu processo de preparação, sua composição farmacêutica e fabricação do medicamento

Country Status (12)

Country Link
US (1) US7722876B2 (pt)
EP (1) EP1504036B1 (pt)
JP (1) JP4405912B2 (pt)
AT (1) ATE514716T1 (pt)
AU (1) AU2003233108A1 (pt)
BR (1) BR0309921A (pt)
CA (1) CA2484704A1 (pt)
CO (1) CO7220324A2 (pt)
DK (1) DK1504036T3 (pt)
GB (1) GB0210783D0 (pt)
NZ (1) NZ536957A (pt)
WO (1) WO2003095493A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006093071A1 (ja) * 2005-02-28 2006-09-08 Genecare Research Institute Co., Ltd. βグルカン合成酵素を有する真菌に対して抗真菌活性を有する抗イディオタイプ抗体、およびその利用
MX2011005481A (es) * 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
WO2011060393A1 (en) * 2009-11-16 2011-05-19 Rasna Therapeutics Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore
ES2634098T3 (es) 2011-01-14 2017-09-26 The Regents Of The University Of California Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos.
LT2731677T (lt) * 2011-07-11 2018-07-10 Glenmark Pharmaceuticals S.A. Antikūnai, kurie prisiriša prie ox40, ir jų panaudojimas
WO2020257625A1 (en) * 2019-06-21 2020-12-24 Rowley Paul A Compositions and methods for inhibiting yeast infections
US20220111018A1 (en) * 2020-06-19 2022-04-14 University Of Idaho Compositions and methods for inhibiting yeast infections
CN111848740B (zh) * 2020-08-04 2023-03-24 南京市妇幼保健院 一种阴道分泌源性多肽及其在抑制白色念珠菌感染中的应用
EP4147716A1 (en) * 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2105618C (en) * 1992-09-07 2009-11-03 Kazuyasu Nakamura Humanized antibodies to ganglioside gm2
WO1998008090A1 (en) * 1995-06-06 1998-02-26 Epigen, Inc. Anti-idiotypic antibodies to an epiglycanin
ES2233974T3 (es) * 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
TR199802227T2 (xx) * 1996-05-04 2000-07-21 Zeneca Limited CEA'ya kar�� monoklonal antikor, bahsedilen antikoru i�eren konj�gatlar ve bunlar�n bir ADEPT siteminde terap�tik kullan�mlar�.
BR9909382A (pt) * 1998-04-03 2000-12-05 Chugai Pharmaceutical Co Ltd Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
DK1125130T3 (da) * 1998-10-29 2006-11-27 Dakocytomation Denmark As Påvisning af syreresistente mikroorganismer i afföringen
JP2002540764A (ja) 1999-02-12 2002-12-03 ジェネティックス・インスチチュート・インコーポレーテッド Ｂ７分子と反応するヒト化免疫グロブリンおよびそれを用いた治療方法
EP1906184A1 (en) * 1999-06-17 2008-04-02 Kyowa Hakko Kogyo Co., Ltd. Diagnostic agent and therapeutic agent for disease related to macrocyte and macrophage
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
EP1130032A1 (en) 2000-02-28 2001-09-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR)
DE10019967A1 (de) * 2000-04-20 2001-10-25 Fenning Biomed Gmbh Dr Antikörper gegen natives gp96, deren Herstellung und Verwendung
NZ523105A (en) * 2000-06-22 2004-07-30 Genentech Inc Agonist anti-trk-C monoclonal antibodies

Also Published As

Publication number Publication date
GB0210783D0 (en) 2002-06-19
US7722876B2 (en) 2010-05-25
US20060280750A1 (en) 2006-12-14
WO2003095493A2 (en) 2003-11-20
JP4405912B2 (ja) 2010-01-27
DK1504036T3 (da) 2011-10-24
AU2003233108A1 (en) 2003-11-11
NZ536957A (en) 2006-07-28
CO7220324A2 (es) 2015-03-20
EP1504036B1 (en) 2011-06-29
ATE514716T1 (de) 2011-07-15
EP1504036A2 (en) 2005-02-09
WO2003095493A3 (en) 2004-06-03
CA2484704A1 (en) 2003-11-20
JP2006506959A (ja) 2006-03-02

Similar Documents

Publication Publication Date Title
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
DE69532605D1 (de) Peptidfragmente von mikrobiellen stressproteinen und daraus hergestellte pharmazeutische zusammensetzungen für die behandlung und vorbeugung von entzündungserkrankungen
ATE517119T1 (de) Einzelketteninsulin
RU2385928C3 (ru) Продуцирование высокоманнозных белков в растительных культурах
WO2003087768A3 (en) Targets for therapeutic intervention identified in the mitochondrial proteome
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
ATE169304T1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
BR0313212A (pt) Aditivos de ácido de polialquileno glicol
BR0309921A (pt) Toxina relacionada a polipetìdeos, peptìdeo-mimético, anticorpo e ácido nucléico com atividade antimicrobiana e antiviral, bem como seu processo de preparação, sua composição farmacêutica e fabricação do medicamento
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
EA200000685A1 (ru) Комплекс ifnar2/ifn
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
DE68918246D1 (de) Verbindungen zur Verhinderung von Thrombose.
DE68917837T2 (de) Peptid-Verbindungen.
SE9604470D0 (sv) Transmembrane component of tight junction
Tamamura et al. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs
CA2032167A1 (en) Dna coding for protein binds to enhancer of.alpha.-fetoprotein gene
ATE359296T1 (de) Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie
HUP9900789A2 (hu) Lefelé irányuló szabályozásra rezisztens C3 konvertáz
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
ATE283279T1 (de) Therapeutische inhaltsstoffe
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
WO2000058438A3 (en) Conformationally constrained peptides
ATE420890T1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE SEJA ACEITO O PEDIDO DE EXAME DA PETICAO NO 018060066665/SP DE 26/06/2006 APRESENTE PETICAO DE DESARQUIVAMENTO, BEM COMO A RESPECTIVA RETRIBUICAO RELATIVA AO CUMPRIMENTO DE EXIGENCIA, EM VIRTUDE DO DISPOSTO NO ART. 33§ UNICO DA LPI.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 018060066665/SP DE 26/06/2006 EM VIRTUDE DO DISPOSTO NO ART. 218, INCISO I DA LPI.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]